Targets › PNPO
1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine; next expected readout Sep 2027.
Catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP). (UniProt, Q9NVS9)
Open in Phaseline: the race on PNPO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Medicure | Pyridoxal Phosphate Pyridoxal 5'-phosphate (active form of vitamin B6) cofactor replacement for PNPO deficienc | PNPO | Phase 3 | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | Sep 2027 |
Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.